Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Docetaxel was the first drug that showed survival benefits when added to the CF regimen, but
it was very toxic. Docetaxel is also has a synergistic anti-cancer effect with S-1, in phase
I/II studies. The use of a docetaxel plus S-1 combination as first-line chemotherapy for
advanced gastric cancer achieved response rates of 46~56% and a median survival time of
14.0~14.3 months.
Based upon this background, the aim of this study is to detect a significant increase in 3
year DFS of disease for the test group (DS) relative to the Control group (SP).